Complete MOTS-c dosage guide covering metabolic optimization protocols, timing, and reconstitution.
MOTS-c is a mitochondria-derived peptide that acts as a metabolic regulator. It activates AMPK, improves insulin sensitivity, promotes fat oxidation, and has shown anti-aging effects in preclinical models. It is unique among peptides because it is encoded in mitochondrial DNA.
Research Disclaimer: This dosage information is for educational and research purposes only. MOTS-c is not FDA-approved for human use (unless otherwise noted). Always consult a qualified healthcare professional before considering any peptide protocol.
| Protocol | Dose | Notes |
|---|---|---|
| Starting Dose | 5mg/week | Conservative starting point. Assess metabolic response and energy levels. |
| Standard Dose | 10mg/week | Most commonly reported effective dose. Can be split into 2x 5mg injections. |
| High Dose | 15–20mg/week | Used in some longevity protocols. Limited human data at this dose range. |
Add 1mL bacteriostatic water to a 10mg vial for a concentration of 10mcg/μL (5mg = 0.5mL = 50 units on a 100-unit syringe).
Morning injection before exercise is most commonly reported. AMPK activation synergizes with fasted exercise for fat oxidation.
Typically run for 4–8 week cycles with 4-week breaks. Some longevity researchers run it year-round at lower doses.
Lyophilized powder: refrigerate at 2–8°C. Reconstituted: refrigerate, use within 30 days.
Use our free peptide calculator to convert your MOTS-c dose into exact syringe units based on your vial concentration.
5–10 mg per week is the most commonly reported research dose. Split into 2 injections per week for more consistent blood levels. Some researchers use 5 mg/day for 5 days on, 2 days off.
Morning before fasted exercise is the most commonly reported timing. AMPK activation from MOTS-c synergizes with the metabolic effects of fasted cardio, potentially amplifying fat oxidation and insulin sensitization.
Most researchers report improved energy and insulin sensitivity within 2–4 weeks. Body composition changes take longer — typically 8–12 weeks of consistent use. Mitochondrial biogenesis effects may take 4–6 weeks to become measurable.
MOTS-c is a mitochondria-derived peptide (MDP) encoded in the mitochondrial genome. It activates AMPK (AMP-activated protein kinase), which regulates cellular energy metabolism, promotes fat oxidation, improves insulin sensitivity, and has been shown to extend lifespan in animal models.
Yes — MOTS-c is commonly stacked with SS-31 (elamipretide) for synergistic mitochondrial support. It is also stacked with Epithalon for broader longevity protocols. The combination of MOTS-c and NAD+ precursors (NMN/NR) is popular for metabolic optimization.
MOTS-c is legal to purchase for research purposes in the United States, Canada, and most of Europe. It is not FDA-approved for human use and is sold strictly as a research chemical. It is prohibited in competitive sports by WADA.
MOTS-c has a favorable safety profile in preclinical studies. The most commonly reported effects in research contexts are mild fatigue and injection site reactions. No serious adverse events have been reported at standard research doses. Long-term safety data in humans is limited.
MOTS-c and NAD+ precursors (NMN, NR) work through complementary but distinct pathways. MOTS-c directly activates AMPK and promotes mitochondrial biogenesis, while NAD+ precursors replenish the NAD+ pool that sirtuins and PARPs depend on. Many researchers use both for comprehensive mitochondrial support.
Purgo Labs provides pharmaceutical-grade research peptides with third-party COAs. Use code HEALTH for 15% off your first order.
Visit Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.